Navigation Links
New advance announced in reducing 'bad' cholesterol
Date:12/8/2011

Scientists from the University of Leicester and University of California Los Angeles (UCLA) have announced a breakthrough advance in tackling dangerous 'bad' cholesterol in the body.

They have filed two patents for developing targeted drugs that would act as a catalyst for lowering levels of 'bad' cholesterol.

Two research papers published by the academics enhance the understanding of the regulation of low-density lipoprotein (LDL) or "bad" cholesterol.

LDL, the so-called "bad" cholesterol, is often linked to medical problems like heart disease, stroke and clogged arteries.

In the body, cells in the liver produce an LDL receptor that binds LDL and removes it from the blood, thereby lowering cholesterol levels.

However, the LDL receptors can be hindered from their mission.

The scientists found that an enzyme called IDOL has been shown to play a key and specific role in the ability of the LDL receptor to bind with 'bad' cholesterol. Therefore targeting the enzyme with drugs would assist the LDL receptors in lowering circulating cholesterol in humans.

Professor John Schwabe, Head of Biochemistry at the University of Leicester, said: "Development of a drug that interferes with IDOL's activity could help lower levels of LDL. Our research has greatly enhanced our understanding of this important process."

Prof John Schwabe, Dr Ben Goult and Dr Louise Fairall at the University of Leicester in collaboration with the University of California Los Angeles (UCLA) published their research in Genes & Development and the Proceeds of the National Academy of Science (PNAS) . The research in the UK was funded by the Wellcome Trust and in the US by NIH and the National Heart Foundation of Australia Overseas Fellowship.

The study in Genes & Development announced the first atomic structural information on IDOL and identified the E2 ligase, UBE2D that works with IDOL to degrade the LDL receptor.

In the second research article published in PNAS, the team elucidated the molecular basis for the stringent specificity of IDOL for the LDL receptor.

Professor Schwabe added: "Remarkably, IDOL only targets three proteins for degradation (all lipoprotein receptors) and this research paper greatly enhances our understanding of this specificity and identifies key residues involved in mediating this interaction.

"A potential future drug that targets IDOL could be prescribed in conjunction with statin drugs, which also cut cholesterol levels by increasing production of the LDL receptor and these two studies make considerable headway towards this. "

The universities have filed 2 patents related to the research findings.


'/>"/>
Contact: Prof. John Schwabe
js336@leicester.ac.uk
01-162-297-030
University of Leicester
Source:Eurekalert  

Related biology news :

1. UCSB scientists make advances in neuroscience and vision research
2. Roche NimbleGen and BGI develop advanced MHC region capture technology for biomedical research
3. Researchers awarded $3.2 million from NIH to pioneer advanced biomolecule discovery technology
4. Bats, dolphins, and mole rats inspire advances in ultrasound technology
5. University Hospitals Case Medical Center unlocks mystery of dystonia with advanced imaging
6. Iowa State engineers establish national panel to advance a carbon negative economy
7. Advanced Medical Care for At-Risk Newborns Nets Economic Benefits
8. Evidence for spinal membrane as a source of stem cells may advance spinal cord treatment
9. An IRB Barcelona project on computational biology receives an ERC Advanced Grant
10. Advance toward a breath test to diagnose multiple sclerosis
11. Leaf litter ants advance case for rainforest conservation in Borneo
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New advance announced in reducing 'bad' cholesterol
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/23/2017)... 23, 2017 The report "Gesture Recognition and Touchless Sensing ... Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is expected ... 29.63% between 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... March 21, 2017 Optimove , ... by retailers such as 1-800-Flowers and AdoreMe, today ... Recommendations and Replenishment. Using Optimove,s machine learning algorithms, ... product and replenishment recommendations to their customers based ... predictions of customer intent drawn from a complex ...
Breaking Biology News(10 mins):
(Date:8/16/2017)... , Aug. 16, 2017  Kingfisher Talent, the ... development, and Virdis Group, global executive search specialists in the ... enables clients to leverage the expertise and reach of both ... here in the Boston biotech hub, ... leadership talent throughout the US, Canada ...
(Date:8/15/2017)... , ... August 15, 2017 , ... ... biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of the new ... steps needed to gain kinetic binding data for a wide range of molecules, ...
(Date:8/15/2017)... , ... August 15, 2017 , ... ... family of 6” modular downlights designed to stay tightly sealed and perform efficiently ... where damp and wet location listings just aren't enough, such as: hospitals; behavioral ...
(Date:8/15/2017)... ... 15, 2017 , ... JULABO USA introduces its new website ... makes it easy to navigate through the site whether you’re in the office, ... information, educational industry content and visit the company’s social media accounts, all on ...
Breaking Biology Technology: